ES2628973T3 - Mutagénesis inducible de genes diana - Google Patents

Mutagénesis inducible de genes diana Download PDF

Info

Publication number
ES2628973T3
ES2628973T3 ES08828508.5T ES08828508T ES2628973T3 ES 2628973 T3 ES2628973 T3 ES 2628973T3 ES 08828508 T ES08828508 T ES 08828508T ES 2628973 T3 ES2628973 T3 ES 2628973T3
Authority
ES
Spain
Prior art keywords
cell
diversification
factor
cells
polilaco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08828508.5T
Other languages
English (en)
Spanish (es)
Inventor
Nancy Maizels
W. Jason Cummings
Munehisa Yabuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Application granted granted Critical
Publication of ES2628973T3 publication Critical patent/ES2628973T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1024—In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES08828508.5T 2007-05-31 2008-06-02 Mutagénesis inducible de genes diana Active ES2628973T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93267207P 2007-05-31 2007-05-31
US932672P 2007-05-31
PCT/US2008/065528 WO2009029315A2 (fr) 2007-05-31 2008-06-02 Mutagenèse inductible de gènes cibles

Publications (1)

Publication Number Publication Date
ES2628973T3 true ES2628973T3 (es) 2017-08-04

Family

ID=40388082

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08828508.5T Active ES2628973T3 (es) 2007-05-31 2008-06-02 Mutagénesis inducible de genes diana

Country Status (6)

Country Link
US (3) US8679845B2 (fr)
EP (1) EP2152861B1 (fr)
JP (1) JP5537420B2 (fr)
CA (1) CA2685714C (fr)
ES (1) ES2628973T3 (fr)
WO (1) WO2009029315A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4482693B2 (ja) * 2005-08-29 2010-06-16 国立大学法人 岡山大学 抗体産生細胞の特異的選択方法
DK3564357T3 (da) 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
US8774494B2 (en) * 2010-04-30 2014-07-08 Complete Genomics, Inc. Method and system for accurate alignment and registration of array for DNA sequencing
US20130244907A1 (en) * 2010-11-18 2013-09-19 National University Corporation Okayama University Method for preparing b cell which produces human-type antibody
WO2012122513A2 (fr) 2011-03-10 2012-09-13 Omeros Corporation Génération d'anticorps monoclonaux anti-fn14 par développement accéléré d'anticorps ex-vivo
EP3392274A1 (fr) 2011-08-12 2018-10-24 Omeros Corporation Anticorps monoclonaux anti-fzd10 et leurs procédés d'utilisation
CA2865506C (fr) 2012-03-15 2021-07-06 Omeros Corporation Composition et procede de diversification de sequences cible
RU2018114903A (ru) 2012-04-06 2019-03-04 Омерос Корпорейшн Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии
KR20220100997A (ko) 2012-06-18 2022-07-18 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
EP2968546B1 (fr) 2013-03-15 2023-09-20 Omeros Corporation Méthodes de génération d'anticorps porteurs de peptide bioactif et compositions les comprenant
US20160369258A1 (en) * 2014-03-11 2016-12-22 University Of Washington Restricting nuclear protein to specific phases of the cell cycle
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
US11845960B2 (en) 2016-09-12 2023-12-19 President And Fellows Of Harvard College Transcription factors controlling differentiation of stem cells
WO2018147432A1 (fr) 2017-02-10 2018-08-16 株式会社カイオム・バイオサイエンス Procédé favorisant la diversification d'une région variable d'anticorps
WO2019195675A1 (fr) 2018-04-06 2019-10-10 President And Fellows Of Harvard College Procédés d'identification d'associations de facteurs de transcription
US12014068B2 (en) 2021-04-27 2024-06-18 Microchip Technology Inc. System and method for double data rate (DDR) chip-kill recovery
WO2022256220A1 (fr) 2021-06-01 2022-12-08 Microchip Technology Inc. Protection d'adresses de mémoire
US11843393B2 (en) 2021-09-28 2023-12-12 Microchip Technology Inc. Method and apparatus for decoding with trapped-block management

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
DE705334T1 (de) * 1993-06-14 1999-12-30 Basf Ag Strenge kontrolle der genexpression in eukaryotischen zellen durch auf tetrazyklin ansprechende promotoren
US7122339B2 (en) * 1998-10-09 2006-10-17 Medical Research Council Method for generating diversity
EP1117774B1 (fr) 1998-10-09 2009-12-30 Medical Research Council Methode de generation de diversite
US7026119B2 (en) * 2000-02-11 2006-04-11 Morphotek, Inc. Methods for generating hypermutable microbes
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
WO2002045494A2 (fr) * 2000-12-06 2002-06-13 Deltagen, Inc. Souris transgeniques comportant des disruptions du gene recepteur du glucagon
NZ534205A (en) 2001-12-22 2006-04-28 Antibody A 4 Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
AU2003214842A1 (en) 2002-01-17 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
WO2004011644A1 (fr) * 2002-07-30 2004-02-05 Riken Methode de promotion d'une recombinaison homologue de cellules somatiques et methode d'elaboration d'un anticorps specifique
WO2005070088A2 (fr) * 2004-01-15 2005-08-04 University Of Georgia Research Foundation, Inc. Sequences chimeriques utilisees a des fins d'expression genetique a specificite tissulaire chez des plantes
EP1568765A1 (fr) 2004-02-23 2005-08-31 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Méthode de diversité génétique dans des cellules capables de conversion génique
US7393923B2 (en) * 2004-11-08 2008-07-01 The Regents Of The University Of California Red-shifted fluorescent proteins mPlum and mRaspberry and polynucleotides encoding the same
JP2008538912A (ja) 2005-04-29 2008-11-13 イナート・ファルマ 遺伝子導入動物および組換え抗体の製造方法
JP4482693B2 (ja) 2005-08-29 2010-06-16 国立大学法人 岡山大学 抗体産生細胞の特異的選択方法
JP2009291073A (ja) 2006-09-22 2009-12-17 Chiome Bioscience Inc 抗体のクラスを変換する方法
JP2008099602A (ja) 2006-10-19 2008-05-01 Institute Of Physical & Chemical Research 抗体遺伝子の可変領域における変異部位の分布状況の調節法

Also Published As

Publication number Publication date
US9273119B2 (en) 2016-03-01
EP2152861A2 (fr) 2010-02-17
US9815885B2 (en) 2017-11-14
CA2685714A1 (fr) 2009-03-05
JP2010528626A (ja) 2010-08-26
CA2685714C (fr) 2016-04-12
AU2008293858A1 (en) 2009-03-05
WO2009029315A2 (fr) 2009-03-05
WO2009029315A3 (fr) 2009-07-02
US20150322134A1 (en) 2015-11-12
JP5537420B2 (ja) 2014-07-02
EP2152861A4 (fr) 2011-12-07
US8679845B2 (en) 2014-03-25
US20100093033A1 (en) 2010-04-15
EP2152861B1 (fr) 2017-03-22
WO2009029315A9 (fr) 2009-04-23
US20160201053A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
ES2628973T3 (es) Mutagénesis inducible de genes diana
WO2017215619A1 (fr) Protéine de fusion produisant une mutation ponctuelle dans une cellule, sa préparation et son utilisation
CN109475109A (zh) 用于使用多个引导rna来破坏免疫耐受性的方法
US20160369258A1 (en) Restricting nuclear protein to specific phases of the cell cycle
EP1780272A1 (fr) Mèthode pour augmenter les hypermutations somatiques, la conversion gènique et le changement de classe par recombinaison
JP2017517250A (ja) 標的エンドヌクレアーゼを用いる哺乳類ゲノムのエピジェネティック修飾
BRPI0809361A2 (pt) Elementos de vetor de expressão recombinante (reves) para melhorar a expressão de proteínas recombinantes em células hospedeiras
ES2336982T3 (es) Procedimiento para la generacion de diversidad.
JP5192153B2 (ja) 遺伝子変換活性状態の細胞における遺伝的多様化のための方法
JP2011504741A (ja) 新規組換え配列
Dauba et al. Long-range control of class switch recombination by transcriptional regulatory elements
JP7026304B2 (ja) 部位特異的ｄｎａ開裂及び修復による標的化原位置タンパク質多様化
US20040115695A1 (en) Methods for generating enhanced antibody producing cell lines with improved growth characteristics
AU2008293858B2 (en) Inducible mutagenesis of target genes
WO2011015916A2 (fr) Vecteurs et composés pour expression d’infliximab recombinant
JP4408278B2 (ja) 新規ｒｎａポリメラーゼｉｉｉプロモーター及びその製造方法並びにその使用方法
TW200411052A (en) Method of transferring mutation into target nucleic acid
Fladerer Investigating nucleolar dynamics in karyotypically normal human cells by fluorescent protein tagging of genes encoding key nucleolar proteins.
Huning Transcriptional Activation of Eukaryotic Promoters via Zinc Finger Protein 143
JP2023521938A (ja) 抗体の発現を増強及び促進する方法
Yoo Characterization of Drosophila Rad51/SpnA protein in DNA binding and embryonic development
Cui RNA/protein interactions during group II intron splicing and toward group II intron targeting in mammalian cells
Hassanzadeh Gh et al. The regulated expression of an intrabody produces a mutant phenotype in Drosophila
KR20240069672A (ko) 대규모 염색체 전달 방법 및 이를 이용한 변형 염색체 및 유기체
Peterson Regulation and Function of the Dscam1 Extended 3’UTR mRNA